The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.
 
Lina Zhang
No Relationships to Disclose
 
Cuizhi Geng
No Relationships to Disclose
 
Yueping Liu
No Relationships to Disclose
 
Jianjun Han
No Relationships to Disclose
 
Meng Han
No Relationships to Disclose
 
Ruixue Huang
No Relationships to Disclose
 
Xianqiao Li
No Relationships to Disclose
 
Ruizhen Luo
No Relationships to Disclose
 
Yuntao Li
No Relationships to Disclose
 
Jie Ma
No Relationships to Disclose
 
Huaihua Qi
No Relationships to Disclose
 
Zunyi Wang
No Relationships to Disclose
 
Xiaochun Wang
No Relationships to Disclose
 
Chao Yang
No Relationships to Disclose
 
Jingqiang Yang
No Relationships to Disclose
 
Lixian Yang
No Relationships to Disclose
 
Jingjing Yu
No Relationships to Disclose
 
Yingzhou Zhang
No Relationships to Disclose
 
Zhisheng Zhang
No Relationships to Disclose
 
Xinping Zhou
No Relationships to Disclose